Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
China's YishengBio chronicles comeback story in Hong Kong IPO while plotting big moves in infectious diseases, cancer
5 years ago
China
Exclusive: Ready to exit 'quiet mode,' joint entity Ventyx debuts its immune modulator pipeline with $114M round
5 years ago
Startups
No more squinting at menus? Visus Therapeutics nabs $36M for presbyopia-correcting eye drop
5 years ago
Biotech IPO market looks to ramp back up as BMS partner Ikena and its immunometabolism therapies eye public offering
5 years ago
Not 3 weeks after taking Humacyte public, Rajiv Shukla launches another blank check company
5 years ago
An Array co-founder re-emerges as CEO of a small academic spinout, looking to remake an old class of cancer drugs
5 years ago
People
With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors
5 years ago
BlackRock pushes Exscientia Series C to $100M as AI biotech boom continues
5 years ago
AI
Peter Thiel-backed psychedelics player ATAI pulls in another nine-figure raise. But they're not ready to talk IPO — yet
5 years ago
Sofinnova Partners stays focused on late-stage deals with a new, $540M crossover fund
5 years ago
The 2021 top 100 biopharma investors: As the pandemic hit and IPOs boomed, VCs swung into action like never before
5 years ago
Special
Fresh off $1B+ Merck deal, Janux locks down first private fundraise for its T cell engagers
5 years ago
A Jennifer Doudna-launched upstart nabs $115M for off-the-shelf CAR-Ts
5 years ago
As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK
5 years ago
Cell/Gene Tx
The next big biotech superstar? Paul Sekhri has some thoughts on that
5 years ago
OrbiMed, biopharma's biggest investor, closes $3.5B in three new private funds
5 years ago
Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria
5 years ago
Deals
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
5 years ago
Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic
5 years ago
With new $106M crossover round, Tenaya preps heart failure programs for the clinic — and maybe an IPO
5 years ago
Cell/Gene Tx
Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0
5 years ago
Cell/Gene Tx
Perceptive's fourth — yes, fourth — SPAC jumps to Nasdaq as the blank check tree continues to ripen
5 years ago
NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal
5 years ago
Cell/Gene Tx
In search of 'household healthcare brands of the future,' Foresite Capital raises $969M to satiate a tech-heavy appetite
5 years ago
First page
Previous page
82
83
84
85
86
87
88
Next page
Last page